Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beta-Phellandrene SCHEMBL154149 | 1.00 | MET (0.31) | MET | |
| Beta-Phellandrene SCHEMBL1306441 | 1.00 | MET (0.31) | MET | |
| Beta-Phellandrene SCHEMBL17629433 | 1.00 | MET (0.31) | MET | |
| SCHEMBL25337903 | 0.86 | CYP3A4 (0.34) | MET | |
| SCHEMBL23268474 | 0.83 | — | — | |
| SCHEMBL10413490 | 0.82 | — | — | |
| Germacrene D SCHEMBL113144 | 0.82 | MET (0.47) | MET | |
| SCHEMBL11031845 | 0.82 | — | — | |
| SCHEMBL10412371 | 0.79 | — | — | |
| SCHEMBL10412372 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114981235-A | Cannabinoid derivatives, precursors and uses | 卡瑞化学技术公司 | 2022-08-30 | — | — | CN | claimed |
| US-20260101926-A1 | VAPORIZING DEVICE | MINSKOFF NOAH MARK (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260021121-A1 | CANNABIS COMPOSITIONS AND METHODS | AIP ASSET MANAGEMENT INC. (CA) | 2026-01-22 | — | — | US | disclosed |
| EP-4604909-A1 | LIPID-BASED MICROCAPSULES | Firmenich SA (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4604741-A1 | WAX-BASED MICROCAPSULES | Firmenich SA (CH) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025132323-A1 | COMPOSITIONS COMPRISING A SUNSCREEN ACTIVE AGENT | DSM-FIRMENICH AG (CH) | 2025-06-26 | — | — | WO | disclosed |
| EP-4568644-A1 | PERFUMING COMPOSITIONS COMPRISING A 2-(ALKYLSULFONYL)OCTAN-4-ONE | Firmenich SA (CH) | 2025-06-18 | — | — | EP | disclosed |
| EP-4558263-A1 | COMPOSITE MICROCAPSULES | Firmenich SA (CH) | 2025-05-28 | — | — | EP | disclosed |
| EP-3339517-B1 | APPARATUS AND METHOD FOR THE ENRICHMENT OF WATER AND AN ASSOCIATED SOLID, WATER-SOLUBLE COMPOSITIONS | SHOWERPLUS ENTW UND VERTRIEBSGESELLSCHAFT MBH (DE) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025082968-A1 | RIBONUCLEIC ACID-BASED MICROCAPSULES | FIRMENICH SA (CH) | 2025-04-24 | — | — | WO | disclosed |
| US-20160089317-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | disclosed |
| US-20160090555-A1 | CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | disclosed |
| US-20160090556-A1 | PRODUCTS COMPRISING MALODOR REDUCTION MATERIALS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | disclosed |
| US-20160090557-A1 | SUBSTRATES COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | disclosed |
| US-20160089464-A1 | MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | disclosed |
| US-20160089462-A1 | FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | disclosed |
| US-20160089318-A1 | PERSONAL CARE COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2016-03-31 | — | — | US | disclosed |
| US-20140370562-A1 | PRODUCTION OF BETA-PHELLANDRENE USING GENETICALLY ENGINEERED CYANOBACTERIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2014-12-18 | — | — | US | disclosed |
| WO-2013119644-A1 | PRODUCTION OF BETA-PHELLANDRENE USING GENETICALLY ENGINEERED CYANOBACTERIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20110257255-A1 | COMPOSITION AND METHOD FOR INHIBITION OF NERVE TRANSMISSION | NEUROQUEST INC. (CA) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260101926-A1 | VAPORIZING DEVICE | SARAF, HSF1, TFPI | MET 3208/4885 |
| US-20110257255-A1 | COMPOSITION AND METHOD FOR INHIBITION OF NERVE TRANSMISSION | GAP43, FNTA, GGPS1 | MET 4580/4885 |
| US-20160089317-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | LPO, QDPR, TYR | MET 3756/4885 |
| US-20260021121-A1 | CANNABIS COMPOSITIONS AND METHODS | CNR2, CNR1, CCT3 | MET 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.